Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy &

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06077773` - Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria	Phase 2
Completed	`NCT04538794` - A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria	Phase 1
Completed	`NCT01803763` - Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients	Phase 2/Phase 3
Recruiting	`NCT05298215` - A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria	Phase 2
Terminated	`NCT04612725` - A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)	Phase 2
Terminated	`NCT05528861` - A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria	Phase 2
Completed	`NCT04109313` - An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU	Phase 2
Completed	`NCT03580356` - A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.	Phase 3
Completed	`NCT03580369` - A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines	Phase 3
Completed	`NCT05030311` - A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines	Phase 3
Recruiting	`NCT06162728` - Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)	Phase 1/Phase 2
Completed	`NCT05107115` - Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine	Phase 2
Recruiting	`NCT06042478` - A Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo and With Omalizumab as Active Control in CSU Adult Patients.	Phase 3
Terminated	`NCT04159701` - A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria	Phase 2
Completed	`NCT03749135` - Dupilumab in Chronic Spontaneous Urticaria	Phase 2
Not yet recruiting	`NCT06396026` - A Study of Efficacy and Safety of TLL-018 in CSU Participants	Phase 3
Completed	`NCT02649218` - A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients	Phase 2
Active, not recruiting	`NCT05368285` - A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria	Phase 2
Completed	`NCT05373355` - Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria.	Phase 1
Not yet recruiting	`NCT06365879` - To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria	Phase 3

NCT number	NCT02477332
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 2
Start date	July 15, 2015
Completion date	June 12, 2017

Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms